The Parkinson’s Disease Virtual Clinic
1. Obeso JA, Rodriguez-Oroz MC, Chana P, et al., The evolution and origin of motor complications in Parkinson's disease, Neurology, 2000;55:S13–20; discussion S21–13.
2. Fahn S, Oakes D, Shoulson I, et al., Levodopa and the progression of Parkinson's disease, N Engl J Med, 2004;351:2498–508.
3. Fahn S, Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA, Arch Neurol, 1999;56:529–35.
4. Stoessl AJ, Continuous dopaminergic therapy in Parkinson disease: time to stride back?, Ann Neurol, 2010;68:3–5.
5. Bibbiani F, Costantini LC, Patel R, Chase TN, Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates, Exp Neurol, 2005;192:73–8.
6. Stowe RL, Ives NJ, Clarke C, et al., Dopamine agonist therapy in early Parkinson's disease, Cochrane Database Syst Rev, 2008:CD006564.
7. Stocchi F, Rascol O, Kieburtz K, et al., Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study, Ann Neurol, 2010;68:18–27.
8. Clarke CE, Worth P, Grosset D, Stewart D, Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease, Parkinsonism Relat Disord, 2009;15:728–41.
9. Chaudhuri KR, Critchley P, Abbott RJ, et al., Subcutaneous apomorphine for on-off oscillations in Parkinson's disease, Lancet, 1988;2:1260.
10. Antonini A, Odin P, Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism Relat Disord, 2009;15(Suppl. 4):S97–100.
11. Kreczy-Kleedorfer B, Wagner M, Bosch S, Poewe W, [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease], Nervenarzt, 1993;64:221–5.
12. De Gaspari D, Siri C, Landi A, et al., Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus, J Neurol Neurosurg Psychiatry, 2006;77:450–3.
13. Hughes AJ, Bishop S, Kleedorfer B, et al., Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years, Mov Disord, 1993;8:165–70.
14. Gancher ST, Nutt JG, Woodward WR, Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance, Mov Disord, 1995;10:37–43.
15. Pietz K, Hagell P, Odin P, Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up, J Neurol Neurosurg Psychiatry, 1998;65:709–16.
16. Kanovsky P, Kubova D, Bares M, et al., Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up, Mov Disord, 2002;17:188–91.
17. Morgante L, Basile G, Epifanio A, et al., Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years, Arch Gerontol Geriatr Suppl, 2004:291–6.
18. Antonini A, Isaias IU, Rodolfi G, et al., A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation, J Neurol, 2011;258:579–85.
19. Antonini A, Isaias IU, Canesi M, et al., Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome, Mov Disord, 2007;22:1145–9.
20. Eggert K, Schrader C, Hahn M, et al., Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications, Clin Neuropharmacol, 2008;31:151–66.
21. Puente V, De Fabregues O, Oliveras C, et al., Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life, Parkinsonism Relat Disord, 2010;16:218–21.
22. Nyholm D, Constantinescu R, Holmberg B, et al., Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations, Acta Neurol Scand, 2009;119:345–8.
23. Volkmann J, Deuschl G, Deep brain stimulation, Handb Clin Neurol, 2007;84:261–77.
24. Katzenschlager R, Hughes A, Evans A, et al., Continuous
subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges, Mov Disord, 2005;20:151–7.
25. Honig H, Antonini A, Martinez-Martin P, et al., Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life, Mov Disord, 2009;24:1468–74.
26. Simkin S, Chaudhuri KR, Selway R, et al., Subthalamic nucleus (STN) deep brain stimulation (DBS) and the non-motor symptom scale (NMSS) in Parkinson’s disease (PD), Presented at: 10th International Congress of Parkinson's Disease and Movement Disorders; October 28–November 2, 2006; Kyoto, Japan.
27. Naidu Y, Tluk S, Martin A, et al., Initiation of apomorphine infusion in advanced Parkinson's disease and effect on non motor symptoms compared to non-invasive strategies, Mov Disord, 2009;24(Suppl. 1):S360.
28. Devos D, Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease, Mov Disord, 2009;24:993–1000.
29. Deuschl G, Schade-Brittinger C, Krack P, et al., A randomized trial of deep-brain stimulation for Parkinson's disease, N Engl J Med, 2006;355:896–908.
30. Nyholm D, Lewander T, Johansson A, et al., Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure, Clin Neuropharmacol, 2008;31:63–73.
31. Toth C, Breithaupt K, Ge S, et al., Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease, Ann Neurol, 2010;68:28–36.
32. Odin P, Hagell P, Shing M, (Eds), Apomorphine in Parkinson's disease, Bremen: Uni-Med Verlag AG; 2008.
33. Temel Y, Kessels A, Tan S, et al., Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review, Parkinsonism Relat Disord, 2006;12:265–272.
34. Kleiner-Fisman G, Herzog J, Fisman DN, et al., Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes, Mov Disord, 2006;21(Suppl. 14):S290–304.
35. Antonini A, Tolosa E, Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management, Expert Rev Neurother, 2009;9:859–67.
26
EUROPEAN NEUROLOGICAL REVIEW SUPPLEMENT
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39